These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 17728907

  • 21. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic.
    Muddu AK, Guha IN, Elsharkawy AM, Mann DA.
    Int J Biochem Cell Biol; 2007; 39(4):695-714. PubMed ID: 17110155
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Fibrosis and cirrhosis reversibility - molecular mechanisms.
    Gieling RG, Burt AD, Mann DA.
    Clin Liver Dis; 2008 Nov; 12(4):915-37, xi. PubMed ID: 18984474
    [Abstract] [Full Text] [Related]

  • 25. Extracts of Lindera obtusiloba induce antifibrotic effects in hepatic stellate cells via suppression of a TGF-beta-mediated profibrotic gene expression pattern.
    Ruehl M, Erben U, Kim K, Freise C, Dagdelen T, Eisele S, Trowitzsch-Kienast W, Zeitz M, Jia J, Stickel F, Somasundaram R.
    J Nutr Biochem; 2009 Aug; 20(8):597-606. PubMed ID: 18824344
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Liver fibrosis: possible involvement of EMT.
    Ikegami T, Zhang Y, Matsuzaki Y.
    Cells Tissues Organs; 2007 Aug; 185(1-3):213-21. PubMed ID: 17587827
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests.
    Gressner OA, Weiskirchen R, Gressner AM.
    Clin Chim Acta; 2007 Jun; 381(2):107-13. PubMed ID: 17399697
    [Abstract] [Full Text] [Related]

  • 30. Vascular deterioration in cirrhosis: the big picture.
    Bosch J.
    J Clin Gastroenterol; 2007 Jun; 41 Suppl 3():S247-53. PubMed ID: 17975472
    [Abstract] [Full Text] [Related]

  • 31. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease.
    McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I.
    Am J Physiol Gastrointest Liver Physiol; 2004 Sep; 287(3):G497-502. PubMed ID: 15331349
    [Abstract] [Full Text] [Related]

  • 32. Platelets contribute to the reduction of liver fibrosis in mice.
    Watanabe M, Murata S, Hashimoto I, Nakano Y, Ikeda O, Aoyagi Y, Matsuo R, Fukunaga K, Yasue H, Ohkohchi N.
    J Gastroenterol Hepatol; 2009 Jan; 24(1):78-89. PubMed ID: 18624898
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Epithelial-mesenchymal transition of biliary epithelial cells in advanced liver fibrosis].
    Schulze F, Schardt K, Wedemeyer I, Konze E, Wendland K, Dirsch O, Töx U, Dienes HP, Odenthal M.
    Verh Dtsch Ges Pathol; 2007 Jan; 91():250-6. PubMed ID: 18314622
    [Abstract] [Full Text] [Related]

  • 35. Cannabinoid receptors as therapeutic targets in the management of liver diseases.
    Mallat A, Lotersztajn S.
    Drug News Perspect; 2008 Sep; 21(7):363-8. PubMed ID: 19259549
    [Abstract] [Full Text] [Related]

  • 36. Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans.
    Weber S, Gressner OA, Hall R, Grünhage F, Lammert F.
    Clin Liver Dis; 2008 Nov; 12(4):747-57, vii. PubMed ID: 18984464
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Rationale and targets for antifibrotic therapies.
    Schuppan D, Popov Y.
    Gastroenterol Clin Biol; 2009 Nov; 33(10-11):949-57. PubMed ID: 19726145
    [Abstract] [Full Text] [Related]

  • 39. Liver fibrosis in vitro: cell culture models and precision-cut liver slices.
    Van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P.
    Toxicol In Vitro; 2007 Jun; 21(4):545-57. PubMed ID: 17289342
    [Abstract] [Full Text] [Related]

  • 40. A target role for mast cell in the prevention and therapy of hepatic fibrosis.
    Shen DZ.
    Med Hypotheses; 2008 Jun; 70(4):760-4. PubMed ID: 17919831
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.